Form 4: EyePoint Pharmaceuticals Director Karen Zaderej Converts Restricted Stock Units to Common Shares

EyePoint Pharmaceuticals Director Karen L. Zaderej acquired 2,000 shares of common stock through the conversion of restricted stock units on July 11, 2025, increasing her direct beneficial ownership to 38,500 shares.

Summary

• Karen L. Zaderej, a Director of EyePoint Pharmaceuticals, Inc. (EYPT), acquired 2,000 shares of common stock.
• This acquisition occurred on July 11, 2025, through the conversion of restricted stock units (RSUs).
• The transaction price for the acquired common stock was $0.00, indicating it was a vesting event rather than a purchase.
• Following this transaction, Ms. Zaderej directly beneficially owns 38,500 shares of EyePoint Pharmaceuticals, Inc. common stock.
• The restricted stock units that were converted were part of a vesting schedule that began on July 11, 2023, with units vesting in three equal annual installments.

Sentiment

Score: 6

Explanation: The document reports a routine insider transaction involving the vesting and conversion of restricted stock units into common stock. This is a pre-planned event and indicates a director's continued equity ownership, which is generally viewed as a neutral to slightly positive sign of alignment with shareholder interests.

Positives

• The conversion of restricted stock units into common shares indicates a pre-planned vesting event, which is a routine part of executive compensation.
• The increase in direct beneficial ownership of common stock by a director aligns the director's interests with those of shareholders.

Future Outlook

No forward-looking statements or guidance are provided.

Industry Context

This filing is a standard disclosure of an insider's equity transaction, common across all publicly traded companies. It does not provide specific insights into broader industry trends or competitors beyond the fact that EyePoint Pharmaceuticals operates in an industry where equity compensation, including restricted stock units, is a common practice for directors and executives.

Comparison to Industry Standards

• The vesting and conversion of restricted stock units are standard practices for executive and director compensation across various industries, including pharmaceuticals. This type of transaction is a routine part of compensation packages designed to align insider interests with shareholder value over time. No specific comparable companies or projects are mentioned to allow for a detailed comparison.

Related Party Transactions

• This document details an insider transaction (acquisition of shares by a director), which is a form of related party dealing.

Stakeholder Impact

• Shareholders: The transaction increases the direct beneficial ownership of common stock by a director, potentially signaling confidence and aligning interests.

Next Steps

• The remaining restricted stock units, if any, will continue to vest in equal annual installments as per the schedule that began on July 11, 2023.

Key Dates

Keywords

EyePoint Pharmaceuticals, EYPT, Karen L. Zaderej, Director, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU conversion, Common Stock, Beneficial Ownership